Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma

Lancet Oncol. 2017 May;18(5):e241-e242. doi: 10.1016/S1470-2045(17)30262-0.

Authors

Junyan Wu¹, Kaifeng Qiu¹, Jianhong Zhu²

Affiliations

¹ Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
² Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China. Electronic address: jianhzhu@yeah.net.

PMID: 28495287
DOI: 10.1016/S1470-2045(17)30262-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Adenocarcinoma*
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab*
Esophageal Neoplasms
Esophagogastric Junction
Humans

Substances

Bevacizumab